Elephas Announces $41.5 Million In Series B Funding

Sep 06, 2022•over 3 years ago

Amount Raised

$41.5 Million

Round Type

series b

MadisonBiotechnology

Description

Elephas Biosciences Corporation (Elephas), a private company, announced today that it has raised $41.5 million in Series B funding. ARCH Venture Partners led the round, and were joined by new investors, Moore Strategic Ventures and Tao Capital Partners. Continuing investments were made by Northpond Ventures, Sands Capital, and WARF Ventures. Prior investments include $20 million from the Series A and $8 million from the founder and early seed investors.

Company Information

Company

Elephas

Location

Madison, Wisconsin, United States

About

Elephas is developing an ex-vivo technology suite to assess how live tumor fragments (LTFs) respond to immunotherapies. We seek to remove the trial-and-error approach to cancer care by harnessing the latest advances in cancer biology, advanced imaging, and artificial intelligence to accelerate drug development and empower clinical decision-making. Our unique approach maintains the native 3-dimensional cellular architecture and micro-environment of the tumor, enabling rapid real-time characterization of live tumor sample response to immunotherapies.

Related People

2 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Elephas Announces $41.5 Million In Series B Funding

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information